Buy on the first test of the breakout.The highest probability play was to buy GILD on the first test of the breakout.by chrisbrecher115
Technicals Saying Take Profits On Gilead Sciences, Inc. (NASDAQ:The biotech sector has had an amazing run in 2014, and you could say that Gilead Sciences, Inc. (NASDAQ:GILD) has lead the charge. The biopharma company is up roughly 40% year to date, and this is after an amazing 100% return for investors in 2013. One could say this is a can't miss stock and rewards its shareholders extremely well. I am not trying to take anything away from the run that Gilead Sciences, Inc. (NASDAQ:GILD) has had. However, looking at the weekly chart I am seeing a bearish pattern being formed, and this indicates to me that there will be downside in the near future. The candlestick that has developed on the chart below is called, a "bearish engulfing candle" and it points to further weakness ahead. So how far can Gilead fall? The first meaningful level that I see is $84, as that is not only the break out area which lead to the recent run up to the all time high of $110.64. But there are also some key proprietary factors which should provide longs a 10% bounce at that level. So while this level may seem like it's far away, know this, the biotech sector can be extremely volatile and this level could be achieved easily in weeks, if not days. Keep a close eye on this chart as the trading action it presents will be fun and profitable! If you only read one email again, make sure it comes from the Elite Round Table. Our FREE market emails contain information that can actually make you money. Ask yourself, what email have you read that can do that? Answer = none. Join our list here. Parm Mann Elite Round Table Follow me on twitter: @ParmMannTraderby Parm551
$GILD Cleared Psychological Pivot Point (Will it last)"Seeing is believing" it does not need a lot of explanation. Its true that price finally closed above PPP level, and seems to print the projected price of C/handle. If market eventually corrects as expected, this is one of the stocks many bears will try to hit hard as it outperformed the market in general. We don't recommend a long term short entry but expect a pull back towards 90-95 which will present another opportunity to re-enter this stock. Stay safe and tuned for more to come. If you like it follow us.by Xafada111
GILD US, Sovaldi against Hepatitis C, LT BUY extreme potentialin at 82 catching early move, still must have Since December 2013 Sovaldi is available in the US and since January 2014 in some European countries while approvals in various significant markets are still pending. Based on its medical importance, I expect more launches in due time. Medicare (US national social insurance program) projects costs of USD 6.5bn in 2015 related to Sovaldi (US only). Until recently, Hepatitis C patients have been treated with a combination of injections and the effect was only to stabilize the disease but not to heal it. In addition, side effects were significant. Sovaldi can be applied in the much easier form of pills. Furthermore, Sovaldi can completely cure Hepatitis C within weeks, as results have shown. The Swiss Department of Health assumes that 1% of total population is infected with the Hepatitis C virus, thus approximately 80’000 people in Switzerland. Extrapolated, Europe would have 7.5m potential patients and worldwide there will be 80m potential patients. Costs of treatment are currently USD 84’000 per patient (in the US). Enormous growth potential here.Longby TBO_ZH2
This week the price went up.But the overall picture has become much more negative. This is a good opportunity to open a short position.Shortby bigrediska1
The movement will continue within the current trend.The movement will continue within the current trend.Shortby bigrediska0
Pullbacks Over Last Yr When RSI Rolling Like This Average -12.5%Currently Only -3% Off High. $IBB $XBIby andrewunknown1
Shorting Gilead SciencesIt appears the bull run from the beginning of 2012 is coming to an end and profit taking is now taking place in Gilead, leading to a correction in its price. Similar set ups/ topping formations can be seen in other Bio-tech stocks and Gilead has one of the biggest pullbacks out of all of them. This can give a nice entry for a short position. Check out my posting of CELG to see another shorting candidate in the Biotech industry.Shortby I43
Momo Slipping at $79-$80 Supp-Turned-Res Pause; Or End of Throwback Attempt to Retake Channel? $IBB $XBIby andrewunknown110
weak sauceThe Dec/Mar highs have capped price post earnings. This thing was halted...everybody was looking for a monster move...the analysts were way off, but the quarter's news appears mostly baked in. This sets up an interesting fade opportunity. (Personally am looking at the May 70-65 Put spread as it really limits risk if wrong and all the extra IV is getting sucked out)by ATMcharts0
GILD Another Bounce Play In the MakingDisclosure: Long Shares @ 68.09 On Friday, Mar 28th, I bought shares of GILD right at the 200-ma for a bounce play, this is one of the strongest biotech stocks and should continue to hold in an uptrend for at least a little while as its hit drug is tracking huge numbers in the market and the pipeline is strong, I think a buy here for a couple dollars bounce could definitely be playable as the RSI is oversold, and the 200 MA is being defended stronglyLongby shomikghosh2221
Breakaway Gap, Opens Below Rising Channel Support: All Day SpentHeaded Lower. $IBB $XBIby andrewunknown0
Gilead Sciences Sets Up As A Beautiful Short The biotech sector is in one of the biggest bubbles since the Dot.com era. Some of the largest biotechnology companies in the world have doubled and tripled their size in the last year. One such stock is Gilead Sciences, Inc. (NASDAQ:GILD). The stock is hovering up 100% from its lows a year ago and has a market cap of $128 billion. Reasons For The Short: 1. Biotech sector in a bubble with cracks emerging. 2. Gildead Sciences is up 100% in the last year with no significant pull backs. 3. The valuation is unstustainable for Gilead Sciences in the near term. 4. The stock has not been able to push through the technically important $85.00 level. Overall, this sector has been an area where money has continued to flow. The music appears like it is coming to a stop. Gilead should have a pull back to $76.00 then $65.00. Gareth Soloway www.InTheMoneyStocks.com Get our detailed entry/exits and live calls as we enter swing trading positions in the Research Center. Shortby InTheMoney_Stocks4
GileadRiding that 20day MA. As long as the market doesn't roll over, remains a good bounce candidate by Robertlesnicki0